Base de dados : MEDLINE
Pesquisa : D12.776.124.486.274.920 [Categoria DeCS]
Referências encontradas : 2353 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 236 ir para página                         

  1 / 2353 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28516949
[Au] Autor:Hill A; DeZern AE; Kinoshita T; Brodsky RA
[Ad] Endereço:Department of Haematology, St. James' University Hospital, Leeds, UK.
[Ti] Título:Paroxysmal nocturnal haemoglobinuria.
[So] Source:Nat Rev Dis Primers;3:17028, 2017 05 18.
[Is] ISSN:2056-676X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Paroxysmal nocturnal haemoglobinuria (PNH) is a clonal haematopoietic stem cell (HSC) disease that presents with haemolytic anaemia, thrombosis and smooth muscle dystonias, as well as bone marrow failure in some cases. PNH is caused by somatic mutations in PIGA (which encodes phosphatidylinositol N-acetylglucosaminyltransferase subunit A) in one or more HSC clones. The gene product of PIGA is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. Clinical manifestations of PNH occur when a HSC clone carrying somatic PIGA mutations acquires a growth advantage and differentiates, generating mature blood cells that are deficient of GPI-anchored proteins. The loss of CD55 and CD59 renders PNH erythrocytes susceptible to intravascular haemolysis, which can lead to thrombosis and to much of the morbidity and mortality of PNH. The accumulation of anaphylatoxins (such as C5a) from complement activation might also have a role. The natural history of PNH is highly variable, ranging from quiescent to life-threatening. Therapeutic strategies include terminal complement blockade and bone marrow transplantation. Eculizumab, a monoclonal antibody complement inhibitor, is highly effective and the only licensed therapy for PNH.
[Mh] Termos MeSH primário: Hemoglobinúria Paroxística/patologia
Hemoglobinúria Paroxística/terapia
Proteínas de Membrana/genética
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/uso terapêutico
Transplante de Medula Óssea
Antígenos CD55/metabolismo
Antígenos CD59/metabolismo
Proteínas Inativadoras do Complemento/metabolismo
Hemoglobinúria Paroxística/genética
Hemoglobinúria Paroxística/metabolismo
Seres Humanos
Mutação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (CD55 Antigens); 0 (CD59 Antigens); 0 (Complement Inactivator Proteins); 0 (Membrane Proteins); 0 (phosphatidylinositol glycan-class A protein); 101754-01-2 (CD59 protein, human); A3ULP0F556 (eculizumab)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1038/nrdp.2017.28


  2 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28345259
[Au] Autor:Blom AM
[Ad] Endereço:Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.
[Ti] Título:The role of complement inhibitors beyond controlling inflammation.
[So] Source:J Intern Med;282(2):116-128, 2017 Aug.
[Is] ISSN:1365-2796
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The complement system is an arm of innate immunity that aids in the removal of pathogens and dying cells. Due to its harmful, pro-inflammatory potential, complement is controlled by several soluble and membrane-bound inhibitors. This family of complement regulators has been recently extended by the discovery of several new members, and it is becoming apparent that these proteins harbour additional functions. In this review, the current state of knowledge of the physiological functions of four complement regulators will be described: cartilage oligomeric matrix protein (COMP), CUB and sushi multiple domains 1 (CSMD1), sushi domain-containing protein 4 (SUSD4) and CD59. Complement activation is involved in both the development of and defence against cancer. COMP expression is pro-oncogenic, whereas CSMD1 and SUSD4 act as tumour suppressors. These effects may be related in part to the complex influence of complement on cancer but also depend on unrelated functions such as the protection of cells from endoplasmic reticulum stress conveyed by intracellular COMP. CD59 is the main inhibitor of the membrane attack complex, and its deficiency leads to complement attack on erythrocytes and severe haemolytic anaemia, which is now amenable to treatment with an inhibitor of C5 cleavage. Unexpectedly, the intracellular pool of CD59 is crucial for insulin secretion from pancreatic ß-cells. This finding is one of several relating to the intracellular functions of complement proteins, which until recently were only considered to be present in the extracellular space. Understanding the alternative functions of complement inhibitors may unravel unexpected links between complement and other physiological systems, but is also important for better design of therapeutic complement inhibition.
[Mh] Termos MeSH primário: Proteínas do Sistema Complemento/fisiologia
[Mh] Termos MeSH secundário: Animais
Antígenos CD59/fisiologia
Proteína de Matriz Oligomérica de Cartilagem/fisiologia
Ativação do Complemento/fisiologia
Proteínas Inativadoras do Complemento/fisiologia
Seres Humanos
Infecção/fisiopatologia
Inflamação/fisiopatologia
Artropatias/fisiopatologia
Proteínas de Membrana/fisiologia
Neoplasias/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (CD59 Antigens); 0 (COMP protein, human); 0 (CSMD1 protein, human); 0 (Cartilage Oligomeric Matrix Protein); 0 (Complement Inactivator Proteins); 0 (Membrane Proteins); 0 (SUSD4 protein, human); 9007-36-7 (Complement System Proteins)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1111/joim.12606


  3 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28339096
[Au] Autor:Arachchillage DRJ; Laffan M
[Ad] Endereço:Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, Hammersmith Hospital, London, UK.
[Ti] Título:Pathogenesis and management of antiphospholipid syndrome.
[So] Source:Br J Haematol;178(2):181-195, 2017 Jul.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Antiphospholipid antibodies are a heterogeneous group of autoantibodies that have clear associations with thrombosis and pregnancy morbidity, and which together constitute the 'antiphospholipid syndrome' (APS). However, the pathophysiology of these complications is not well understood and their heterogeneity suggests that more than one pathogenic process may be involved. Diagnosis remains a combination of laboratory analysis and clinical observation but there have been significant advances in identifying specific pathogenic features, such as domain I-specific anti-ß2-glycoprotein-I antibodies. This in turn has pointed to endothelial and complement activation as important factors in the pathogenesis of APS. Consequently, although anticoagulation remains the standard treatment for thrombotic APS and during pregnancy, the realisation that these additional pathways are involved in the pathogenesis of APS has significant implications for treatment: agents acting outside the coagulation system, such as hydroxychloroquine for pregnancy complications and sirolimus as an inhibitor of the mammalian target of rapamycin (mTOR) pathway, are now under evaluation and represent a radical change in thinking for haematologists. Conventional anticoagulation is also under challenge from new, direct acting anticoagulants. This review will provide a comprehensive overview of the evolving understanding of APS pathogenesis and how this and novel therapeutics will alter diagnosis and management.
[Mh] Termos MeSH primário: Síndrome Antifosfolipídica/etiologia
[Mh] Termos MeSH secundário: Anticoagulantes/uso terapêutico
Síndrome Antifosfolipídica/tratamento farmacológico
Autoanticorpos/imunologia
Proteínas Inativadoras do Complemento/uso terapêutico
Inibidores Enzimáticos/uso terapêutico
Feminino
Previsões
Seres Humanos
Hidroxicloroquina/uso terapêutico
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Imunossupressores/uso terapêutico
Gravidez
Complicações na Gravidez/tratamento farmacológico
Complicações na Gravidez/etiologia
Rituximab/uso terapêutico
Sirolimo/uso terapêutico
Trombose/tratamento farmacológico
Trombose/etiologia
Trombose/imunologia
beta 2-Glicoproteína I/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Autoantibodies); 0 (Complement Inactivator Proteins); 0 (Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Immunosuppressive Agents); 0 (beta 2-Glycoprotein I); 4F4X42SYQ6 (Rituximab); 4QWG6N8QKH (Hydroxychloroquine); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14632


  4 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28094185
[Au] Autor:Wen Q; Lu Y; Chao Z; Chen DF
[Ad] Endereço:Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, PR China.
[Ti] Título:Anticomplement triterpenoids from the roots of Ilex asprella.
[So] Source:Bioorg Med Chem Lett;27(4):880-886, 2017 Feb 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Five new (1-5) and twenty-eight known (6-33) triterpenoids were isolated from the roots of Ilex asprella. The structures of the new compounds were elucidated by the detailed spectral analysis. The ursane and oleanane triterpenoids were found to show anticomplement activity with some structure-activity relationships. Several triterpenoids (1-3, 6-7) exhibited potent anticomplement activity with the CH and AP values of 0.058-0.131mg/mL and 0.080-0.444mg/mL, respectively. It was found that caffeoyl group could enhance activity remarkably, followed by coumaroyl and feruloyl group. The 28-carboxyl group was also important to anticomplement activity for the triterpenoids. However, the triterpenoids with lactone ring (4, 9-14) exhibited weak activity and triterpenoid glycosides (5, 23-33) showed no inhibition. The targets of several bioactive triterpenoids in complement activation cascade were identified as well.
[Mh] Termos MeSH primário: Proteínas Inativadoras do Complemento/química
Ilex/química
Triterpenos/química
[Mh] Termos MeSH secundário: Animais
Proteínas Inativadoras do Complemento/isolamento & purificação
Proteínas Inativadoras do Complemento/farmacologia
Eritrócitos/citologia
Eritrócitos/efeitos dos fármacos
Eritrócitos/metabolismo
Hemólise/efeitos dos fármacos
Ilex/metabolismo
Espectroscopia de Ressonância Magnética
Conformação Molecular
Ácido Oleanólico/análogos & derivados
Ácido Oleanólico/química
Raízes de Plantas/química
Raízes de Plantas/metabolismo
Ovinos
Relação Estrutura-Atividade
Triterpenos/isolamento & purificação
Triterpenos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement Inactivator Proteins); 0 (Triterpenes); 0 (anticomplement); 0 (oleanane); 0 (ursane); 6SMK8R7TGJ (Oleanolic Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170704
[Lr] Data última revisão:
170704
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170118
[St] Status:MEDLINE


  5 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27688119
[Au] Autor:Sui ZH; Li MF; Sun L
[Ad] Endereço:Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China; University of Chinese Academy of Sciences, Beijing, China.
[Ti] Título:Tongue sole (Cynoglossus semilaevis) CD59: A complement inhibitor that binds bacterial cells and promotes bacterial escape from the killing of fish serum.
[So] Source:Fish Shellfish Immunol;58:442-448, 2016 Nov.
[Is] ISSN:1095-9947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CD59 is a complement regulatory protein that inhibits the formation of membrane attack complex of complement. In this study, we examined the expression and activity of tongue sole (Cynoglossus semilaevis) CD59 (CsCD59). CsCD59 possesses the conserved structural features of CD59 and shares 33%-46% sequence identities with other fish CD59. Expression of CsCD59 was high in liver, spleen, and muscle, and was stimulated by infection of bacterial pathogens. Recombinant CsCD59 (rCsCD59) exhibited an apparent inhibition effect on the activation of tongue sole serum complement. ELISA and microscopy detected binding of rCsCD59 to a number of Gram-negative and Gram-positive bacteria. Interaction with rCsCD59 did not affect bacterial viability but significantly enhanced bacterial resistance against the killing effect of fish serum. Together these results indicate that fish CD59 may to some degrees facilitate a general escape of bacteria from complement-mediated immunity.
[Mh] Termos MeSH primário: Antígenos CD59/genética
Proteínas Inativadoras do Complemento/genética
Doenças dos Peixes/genética
Proteínas de Peixes/genética
Linguados
Infecções por Bactérias Gram-Negativas/veterinária
Infecções por Bactérias Gram-Positivas/veterinária
[Mh] Termos MeSH secundário: Animais
Sequência de Bases
Antígenos CD59/metabolismo
Proteínas Inativadoras do Complemento/metabolismo
Doenças dos Peixes/imunologia
Doenças dos Peixes/microbiologia
Proteínas de Peixes/metabolismo
Regulação da Expressão Gênica
Bactérias Gram-Negativas/fisiologia
Infecções por Bactérias Gram-Negativas/genética
Infecções por Bactérias Gram-Negativas/imunologia
Infecções por Bactérias Gram-Negativas/microbiologia
Bactérias Gram-Positivas/fisiologia
Infecções por Bactérias Gram-Positivas/genética
Infecções por Bactérias Gram-Positivas/imunologia
Infecções por Bactérias Gram-Positivas/microbiologia
Alinhamento de Sequência/veterinária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD59 Antigens); 0 (Complement Inactivator Proteins); 0 (Fish Proteins)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161001
[St] Status:MEDLINE


  6 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lima, Walter S
PubMed Central Texto completo
Texto completo
[PMID]:27515662
[Au] Autor:Silva NC; Vale VF; Franco PF; Gontijo NF; Valenzuela JG; Pereira MH; Sant'Anna MR; Rodrigues DS; Lima WS; Fux B; Araujo RN
[Ad] Endereço:Departamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
[Ti] Título:Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits classical and alternative complement pathways.
[So] Source:Parasit Vectors;9(1):445, 2016 Aug 11.
[Is] ISSN:1756-3305
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Rhipicephalus (Boophilus) microplus is the main ectoparasite affecting livestock worldwide. For a successful parasitism, ticks need to evade several immune responses of their hosts, including the activation of the complement system. In spite of the importance of R. microplus, previous work only identified one salivary molecule that blocks the complement system. The current study describes complement inhibitory activities induced by R. microplus salivary components and mechanisms elicited by putative salivary proteins on both classical and alternative complement pathways. RESULTS: We found that R. microplus saliva from fully- and partially engorged females was able to inhibit both pathways. Saliva acts strongly at the initial steps of both complement activation pathways. In the classical pathway, the saliva blocked C4 cleavage, and hence, deposition of C4b on the activation surface, suggesting that the inhibition occurs at some point between C1q and C4. In the alternative pathway, saliva acts by binding to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and reducing C3b production and deposition as well as cleavage of factor B. Saliva has no effect on formation or decay of the C6 to C8 components of the membrane attack complex. CONCLUSION: The saliva of R. microplus is able to inhibit the early steps of classical and alternative pathways of the complement system. Saliva acts by blocking C4 cleavage and deposition of C4b on the classical pathway activation surface and, in the alternative pathway, saliva bind to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and the production and deposition of additional C3b.
[Mh] Termos MeSH primário: Proteínas Inativadoras do Complemento/metabolismo
Via Alternativa do Complemento/efeitos dos fármacos
Via Clássica do Complemento/efeitos dos fármacos
Rhipicephalus/imunologia
Saliva/metabolismo
[Mh] Termos MeSH secundário: Animais
Evasão da Resposta Imune
Tolerância Imunológica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Complement Inactivator Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160813
[St] Status:MEDLINE
[do] DOI:10.1186/s13071-016-1726-8


  7 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27153814
[Au] Autor:Rangaswamy US; Cotter CR; Cheng X; Jin H; Chen Z
[Ad] Endereço:1​ MedImmune LLC, Mountain View, California, USA.
[Ti] Título:CD55 is a key complement regulatory protein that counteracts complement-mediated inactivation of Newcastle Disease Virus.
[So] Source:J Gen Virol;97(8):1765-70, 2016 Aug.
[Is] ISSN:1465-2099
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Newcastle disease virus (NDV) is being developed as an oncolytic virus for virotherapy. In this study we analysed the regulation of complement-mediated inactivation of a recombinant NDV in different host cells. NDV grown in human cells was less sensitive to complement-mediated virus inactivation than NDV grown in embryonated chicken eggs. Additionally, NDV produced from HeLa-S3 cells is more resistant to complement than NDV from 293F cells, which correlated with higher expression and incorporation of complement regulatory proteins (CD46, CD55 and CD59) into virions from HeLa-S3 cells. Further analysis of the recombinant NDVs individually expressing the three CD molecules showed that CD55 is the most potent in counteracting complement-mediated virus inactivation. The results provide important information on selecting NDV manufacture substrate to mitigate complement-mediated virus inactivation.
[Mh] Termos MeSH primário: Antígenos CD55/metabolismo
Proteínas Inativadoras do Complemento/metabolismo
Proteínas do Sistema Complemento/metabolismo
Interações Hospedeiro-Patógeno
Fatores Imunológicos/metabolismo
Vírus da Doença de Newcastle/imunologia
Vírus da Doença de Newcastle/fisiologia
[Mh] Termos MeSH secundário: Animais
Antígenos CD59/metabolismo
Linhagem Celular
Galinhas
Seres Humanos
Proteína Cofatora de Membrana/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD55 Antigens); 0 (CD59 Antigens); 0 (Complement Inactivator Proteins); 0 (Immunologic Factors); 0 (Membrane Cofactor Protein); 9007-36-7 (Complement System Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160508
[St] Status:MEDLINE
[do] DOI:10.1099/jgv.0.000498


  8 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27140685
[Au] Autor:Mu LH; Zhao JY; Zhang J; Liu P
[Ad] Endereço:a Department of Clinical Pharmacology , General Hospital of PLA , Beijing 100853 , China.
[Ti] Título:Cycloartane triterpenes from Beesia calthaefolia and their anticomplement structure-activity relationship study.
[So] Source:J Asian Nat Prod Res;18(11):1101-7, 2016 Nov.
[Is] ISSN:1477-2213
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Fifteen cycloartane triterpenes were isolated from Beesia calthaefolia and among them one was new cycloartane triterpenoid. The structure of new compound was determined by the application of spectroscopic analyses and chemical methods. The fifteen compounds were evaluated for their anticomplement activity by classic pathway. The structure-activity relationship analysis indicated that the configurations of 12-OH is preferable to be α than ß, and 18-OH can decrease while 15-OH can increase the anticomplement activity, but saponin with both 15-OH and 18-OH lost most of its activity. The glycosyl moiety of most isolated cycloartane triterpenes is xylosyl. When xylosyl was substituted by glucosyl or galactosyl, their anticomplement activities were decreased or increased, respectively. Further structure-activity relationship (SAR) studies must be carried out to achieve general conclusions regarding the effect of further functionalizations on the anticomplement saponins.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/isolamento & purificação
Medicamentos de Ervas Chinesas/farmacologia
Ranunculaceae/química
Saponinas/isolamento & purificação
Saponinas/farmacologia
Triterpenos/isolamento & purificação
Triterpenos/farmacologia
[Mh] Termos MeSH secundário: Proteínas Inativadoras do Complemento/farmacologia
Medicamentos de Ervas Chinesas/química
Glucosídeos
Estrutura Molecular
Saponinas/química
Relação Estrutura-Atividade
Triterpenos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 ((20S*, 24R*)-epoxy-9,19-cyclolanostane-3beta,15alpha,16beta,18,25-pentaol-3-O-beta-D-glucopyranoside); 0 (Complement Inactivator Proteins); 0 (Drugs, Chinese Herbal); 0 (Glucosides); 0 (Saponins); 0 (Triterpenes); 0 (anticomplement); 511-64-8 (cycloartane)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170125
[Lr] Data última revisão:
170125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160504
[St] Status:MEDLINE
[do] DOI:10.1080/10286020.2016.1174698


  9 / 2353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26359936
[Au] Autor:Tsai HM
[Ad] Endereço:iMAH Hematology Associates, New Hyde Park, NY.
[Ti] Título:Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension?
[So] Source:J Clin Hypertens (Greenwich);18(4):359-60, 2016 Apr.
[Is] ISSN:1751-7176
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Pressão Sanguínea/efeitos dos fármacos
Proteínas Inativadoras do Complemento/uso terapêutico
Hipertensão Maligna/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Hipertensão Maligna/fisiopatologia
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Complement Inactivator Proteins); 0 (anticomplement)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170113
[Lr] Data última revisão:
170113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150912
[St] Status:MEDLINE
[do] DOI:10.1111/jch.12664


  10 / 2353 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26305784
[Au] Autor:Zhao JY; Mu LH; Dong XZ; Hu Y; Liu P
[Ad] Endereço:a Department of Clinical Pharmacology , General Hospital of PLA , Beijing 100853 , P.R. China.
[Ti] Título:One new cycloartane triterpene glycoside from Beesia calthaefolia.
[So] Source:Nat Prod Res;30(3):316-21, 2016.
[Is] ISSN:1478-6427
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:One new cycloartane triterpene glycoside (1) was isolated from the whole plant of Beesia calthaefolia. Its structure was elucidated on the basis of extensive spectroscopic data analysis. Its inhibitory effect was measured by the classical pathway of the complement system, and compared with those of known related cycloartane glycosides 2 and 3, previously isolated by us from the same plant. Compounds 1 and 2 exhibited inhibitory activity of complement system with IC50 of 395.3 and 214 µM, respectively. The results suggested that OH at C-12, C-18 and C-15 along with the polarity could affect the inhibitory activity.
[Mh] Termos MeSH primário: Glicosídeos/química
Ranunculaceae/química
Triterpenos/química
[Mh] Termos MeSH secundário: Animais
Proteínas Inativadoras do Complemento/química
Proteínas Inativadoras do Complemento/farmacologia
Via Clássica do Complemento/efeitos dos fármacos
Avaliação Pré-Clínica de Medicamentos/métodos
Eritrócitos/efeitos dos fármacos
Glicosídeos/isolamento & purificação
Glicosídeos/farmacologia
Concentração Inibidora 50
Espectroscopia de Ressonância Magnética
Estrutura Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 ((20S*, 24S*)-16beta, 24;20,24-diepoxy-9,19-cycloanostane-3beta,12beta,25-triol-3-O-(beta-D-glucopyranosyl-(1-3))-beta-D-xylopyranoside); 0 (Complement Inactivator Proteins); 0 (Glycosides); 0 (Triterpenes); 511-64-8 (cycloartane)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151215
[Lr] Data última revisão:
151215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150826
[St] Status:MEDLINE
[do] DOI:10.1080/14786419.2015.1058791



página 1 de 236 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde